Brief: Erasca And Tango Therapeutics Enter Into Clinical Collaboration To Evaluate Combination Of ERAS-0015 And Vopimetostat
05/03/2026 12:02
March 5 (Reuters) - Erasca Inc ERAS.O: ERASCA AND TANGO THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATION OF ERAS-0015 AND VOPIMETOSTAT ERASCA INC: CO WILL SUPPLY ERAS-0015 FREE OF CHARGE, AND TANGO WILL BE TRIAL SPONSOR ERASCA INC: EACH COMPANY WILL RETAIN COMMERCIAL RIGHTS TO THEIR RESPECTIVE COMPOUND Source text: ID:nGNX1jS7sS Further company coverage: ERAS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tango Therapeutics
See all newsBrief: Tango Therapeutics, Inc. Approved A Strategic Reprioritization Of The Company’S Research And Development Activities
Brief: Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Tango Therapeutics - Files Prospectus To Sell Up To $400 Million In Common Stock
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,